Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by Bfsg LLC

Bfsg LLC lifted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 41.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,554 shares of the company’s stock after buying an additional 7,191 shares during the quarter. Bfsg LLC’s holdings in Elanco Animal Health were worth $297,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of ELAN. AM Squared Ltd purchased a new stake in shares of Elanco Animal Health in the third quarter valued at approximately $34,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Elanco Animal Health in the third quarter valued at approximately $35,000. Farther Finance Advisors LLC boosted its stake in shares of Elanco Animal Health by 158.7% in the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after buying an additional 2,044 shares in the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Elanco Animal Health by 89.9% in the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after buying an additional 1,601 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Elanco Animal Health by 2,129.2% in the third quarter. Blue Trust Inc. now owns 3,968 shares of the company’s stock valued at $57,000 after buying an additional 3,790 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Barclays lifted their price target on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Morgan Stanley decreased their target price on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 29th. UBS Group assumed coverage on Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 target price on the stock. Stifel Nicolaus decreased their target price on Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Leerink Partners assumed coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Elanco Animal Health currently has an average rating of “Hold” and a consensus price target of $16.29.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $11.32 on Wednesday. Elanco Animal Health Incorporated has a fifty-two week low of $10.77 and a fifty-two week high of $18.80. The stock has a market cap of $5.59 billion, a price-to-earnings ratio of 28.29, a price-to-earnings-growth ratio of 2.69 and a beta of 1.42. The business has a fifty day moving average of $11.88 and a 200-day moving average of $13.13. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.